Abstract | AIM: The feasibility of vaccination in liver transplant recipients is highly controversial, and the present study aimed to investigate the efficacy of a 1-year extended, monthly vaccine prophylaxis protocol of a second-generation recombinant vaccine for transplant recipients. METHODS: RESULTS: The vaccination protocol was initiated a mean of 54 months (range, 13-124) after liver transplantation, and all patients tolerated the vaccination well without adverse effects. The overall hepatitis B virus (HBV) recurrence rate was 5% (2/39) based on hepatitis B surface antigen positivity, and 2% (1/39) based on HBV DNA detectability. Six (15%) patients showed a good response to vaccination with an increase in the HBsAb titer greater than 100 IU/L at the end of vaccination, but only three (8%) maintained an adequate HBsAb level to spare HBIG during the 2-year observation period. CONCLUSION: While a few patients demonstrated an adequate response to vaccination, the clinical indication for the HBV vaccination for liver transplant recipients is currently minimal.
|
Authors | Junichi Togashi, Nobuhisa Akamatsu, Yasuhiko Sugawara, Junichi Kaneko, Sumihito Tamura, Tomohiro Tanaka, Junichi Arita, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo |
Journal | Hepatology research : the official journal of the Japan Society of Hepatology
(Hepatol Res)
Vol. 46
Issue 3
Pg. E51-9
(Mar 2016)
ISSN: 1386-6346 [Print] Netherlands |
PMID | 25899139
(Publication Type: Journal Article)
|
Copyright | © 2015 The Japan Society of Hepatology. |